September 13, 2021 — The European Society of Cardiology (ESC) and European Association for...
Heart Valve Technology
This channel includes news and new device innovations about heart valve technologies, including the aortic valve, mitral valve, pulmonic valve, and tricuspid valve. This includes information on transcatheter valve technologies like transcatheter aortic valve replacement (TAVR, or implantation TAVI), transcatheter mitral valve repair or replacement (TMVR), transcatheter and surgical valve repairs, and surgical replacement valves. Newer devices are now being used for transcatheter tricuspid valve repair replacement (TTVR).
-
-
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with...
-
Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program...
-
June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral and tricuspid programs, presented as part of the late-breaking clinical trials...
Non-invasive evaluation of heart valves using echocardiography first, and other cardiac imaging techniques when needed, is the key evaluation of heart valves in the new ESC and European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease. Photo by Dave Fornell.
News | Structural Heart | September 13, 2021
September 13, 2021 — The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (...
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.
News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart...
Leveraging Vivasure Medical’s PerQseal vascular closure device technology, PerQseal Blue consists of an intravascular patch designed to seal the vessel from the inside, returning the vein to its natural state after it dissolves over time, so no foreign bodies are left behind.
News | Vascular Closure Devices | July 15, 2021
Vivasure Medical is Developing a Sutureless Venous Closure Device for Transcatheter Valve Procedures
July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully...
Videos | Structural Heart | July 14, 2021
Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University...
The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.
Feature | Heart Valve Technology | July 08, 2021
July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve...
The balloon inflation to deploy an Edwards Lifesciences Sapien 3 TAVR valve in a failed surgical tricuspid valve. This valve-in-valve (VIV) procedures was performed at Beaumont in a 34-year-old female patient who was determined to be too high of a surgical risk for a second surgical valve replacement.
News | Structural Heart | June 29, 2021
June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare...
Blog | Structural Heart | June 08, 2021
It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts...
The 30-day outcomes from the TRISCEND study of the transfemoral Evoque tricuspid valve replacement system demonstrated technical feasibility and an acceptable safety profile, along with improvements in tricuspid regurgitation (TR) and symptoms in patients with clinically significant TR.
News | Structural Heart | June 07, 2021
June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral...
Feature | Structural Heart | June 02, 2021 | Dave Fornell, Editor
June 2, 2021 — The startup company HLT is a part of the Bracco Group, which is developing a new transcatheter aortic...
The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.
News | Heart Valve Technology | June 02, 2021
June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart...
Videos | Congenital Heart | May 26, 2021
Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, explains some of the new...
The Acurate neo2 TAVR valve design enhancements include a 60% larger outer sealing skirt to conform to challenging anatomies. This has minimized paravalvular leaks and imporved clinical outcomes compared to the previous-generation Acurate neo Aortic Valve System.
Feature | Structural Heart | May 26, 2021
May 26, 2021 — Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress for the updated...
An Edward Lifesciences Sapien TAVR valve during an implant procedure on angiography. There are still questions on how to best anticoagulate TAVR patients and the ATLANTIS study found Eliquis is not a good solution.
News | Structural Heart | May 15, 2021
May 15, 2021 — The anticoagulant apixaban (Eliquis) was not superior to standard of care following transcatheter aortic...
Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire (solid yellow line). Image courtesy of Kendra Grubb, M.D.
Feature | Structural Heart | May 13, 2021 | By Dave Fornell, Editor
The mitral valve anatomy is extremely complex, which has caused many challenges for transcatheter mitral valve...
Videos | Structural Heart | May 13, 2021
Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, and principle...
